| Expression pattern: |
UP |
| Associated gene: |
CXCL12, AGO2 |
| Associated microRNA: |
miR-141-3p |
| Biological function: |
Promotes gastric cancer cell proliferation, migration, invasion, EMT, stemness, metastasis and immune evasion; promotes anti-PD-1 resistance. |
| Molecular mechanism: |
Acts as a miRNA sponge for miR-141-3p to increase CXCL12 expression, promoting MDSC infiltration and impairing CD8+ T-cell function. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); stemness (promotes); immune regulation (other); ceRNA regulation (promotes); drug resistance (promotes) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; ISH (In Situ Hybridization); Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; IF (Immunofluorescence); Western Blot; IHC (Immunohistochemistry); Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; H&E Staining; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circDLG1 expression was associated with worse PFS/adverse prognosis in gastric cancer patients treated with anti-PD-1 therapy and with aggressive tumor phenotype. |
| Description: |
circDLG1 (hsa_circ_0008583) is upregulated in metastatic and anti-PD-1-resistant gastric cancer tissues. It promotes proliferation, invasion/metastasis and immune evasion by sponging miR-141-3p to upregulate CXCL12, driving MDSC infiltration and anti-PD-1 resistance; high circDLG1 predicts worse PFS in anti-PD-1-treated patients. |
| Confidence score: |
0.8941 |